Immunology CROs in South Korea

South Korea's first CRO founded in 1997, providing comprehensive Phase I-IV clinical development solutions including regulatory affairs, data management, pharmacovigilance and medical translation.

South Korean CRO specializing in clinical trial management and data services for pharmaceutical companies developing products for both Korean and global regulatory submissions.

South Korean biopharmaceutical company providing biosimilar development and cGMP biologics manufacturing with one of the largest mammalian cell culture facilities in the world.

South Korean full-service CRO providing clinical development services from Phase I through post-marketing with bioanalytical capabilities and strong ties to Korean academic medical centers.

South Korea's largest clinical CRO and Tigermed subsidiary, delivering full-scope clinical services with 1,200+ successful projects across pharmaceuticals, biotech, and medical devices.

South Korean CRO providing Phase I-IV clinical development, bioanalytical services, and regulatory consulting with particular expertise in simultaneous MFDS-FDA-EMA regulatory submissions.

Seoul-based full-service Korean CRO with 400 clinical trial experts and experience across 1,600+ studies including 180+ global multi-center trials.

South Korean biosimilar developer and CDMO providing biologics development, manufacturing, and analytical services with a portfolio of approved biosimilar products across global markets.

Leading CDMO providing end-to-end biopharmaceutical manufacturing services including cell line development, process development, and commercial manufacturing at massive scale.

Syneos Health's Korean operations providing full-service clinical development support for Korean and global pharmaceutical companies conducting trials in South Korea and APAC markets.

South Korean genomics and CRO company providing next-generation sequencing, genomic analysis, and precision medicine research services alongside clinical biomarker and pharmacogenomics programs.